Kymera Therapeutics (NASDAQ:KYMR) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Kymera Therapeutics (NASDAQ:KYMR) posted its quarterly earnings data on Thursday. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.06), FiscalAI reports. Kymera Therapeutics had a negative return on equity of 22.65% and a negative net margin of 285.33%. The firm had revenue of $1.35 million for the quarter, compared to the consensus estimate of $3.28 million. During the same quarter last year, the firm earned ($0.94) EPS. The company’s revenue was up .0% compared to the same quarter last year.

Here are the key takeaways from Kymera Therapeutics’ conference call:

• KT-579 showed robust human proof of mechanism: once-daily dosing produced more than 90% IRF5 degradation in the top dose cohorts, including comparable effects in skin, with substantial reductions across inflammatory cytokine, interferon, and B-cell pathways.
• KT-579 was well tolerated in the phase I study, with a safety profile comparable to placebo, no serious adverse events, no discontinuations, and no infection imbalance. Kymera plans to advance the program into the approximately 30-patient LUMORA phase Ib lupus trial by early 2027.
• The company completed the 16-week placebo-controlled portion of the KT-621 BROADEN2 atopic dermatitis study and expects to report results by year-end; 98% of eligible patients entered the 52-week open-label extension. Kymera is preparing for a potential phase III AD study beginning by mid-2027, subject to supportive results and FDA alignment.
• KT-621 asthma enrollment is progressing as planned, with phase IIb BREADTH results expected in late 2027, while partner programs KT-485 and KT-200 also remain on track. Management emphasized potential expansion into additional type 2 inflammatory diseases, but detailed plans will depend on upcoming clinical data.
• Kymera ended September with approximately $1.6 billion in cash and investments, providing a projected runway into 2029 and funding planned KT-621 phase III preparations, the KT-579 lupus study, and continued pipeline research without near-term financing pressure.

Kymera Therapeutics Stock Up 3.3%

Shares of Kymera Therapeutics stock traded up $4.03 during midday trading on Friday, hitting $126.63. The company had a trading volume of 1,591,325 shares, compared to its average volume of 831,356. The stock has a market cap of $10.53 billion, a price-to-earnings ratio of -34.98 and a beta of 1.98. The company has a fifty day simple moving average of $114.93 and a 200 day simple moving average of $96.35. Kymera Therapeutics has a 12-month low of $55.66 and a 12-month high of $130.05.

Insider Buying and Selling

In related news, insider Brian Adams sold 6,371 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the completion of the sale, the insider directly owned 50,254 shares in the company, valued at $5,871,174.82. This trade represents a 11.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the sale, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. This represents a 4.31% decrease in their position. The SEC filing for this sale provides additional information. 15.98% of the stock is owned by company insiders.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, showing deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers, and a favorable safety profile. The data support continued development of the company’s immunology pipeline. Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
• Positive Sentiment: Truist Financial reaffirmed its “buy” rating and raised its price target from $136 to $150, implying further upside based on the current trading level. Truist Securities Adjusts Price Target on Kymera Therapeutics
• Positive Sentiment: BTIG Research raised its target from $134 to $139 and maintained a “buy” rating, adding to the favorable analyst sentiment.
• Neutral Sentiment: Kymera provided a Phase 1 update on the formulation study for KT-621, offering investors additional information on the program’s ongoing clinical development. KT-621 Formulation Study Update
• Neutral Sentiment: RBC increased its price target from $112 to $116 but retained a “sector perform” rating, signaling limited conviction at the current valuation.
• Negative Sentiment: Third-quarter results missed expectations: adjusted loss was $1.32 per share versus a $1.26 consensus loss, while revenue of $1.35 million was below the $3.28 million estimate. The net loss also widened year over year, highlighting ongoing cash-burn and execution risks. Kymera Therapeutics Q3 Net Loss Widens

Analyst Ratings Changes

KYMR has been the topic of several analyst reports. Guggenheim lifted their price target on shares of Kymera Therapeutics from $135.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, August 31st. TD Cowen raised Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Piper Sandler reiterated an “overweight” rating and set a $140.00 price objective on shares of Kymera Therapeutics in a report on Wednesday, September 23rd. BTIG Research increased their price objective on Kymera Therapeutics from $134.00 to $139.00 and gave the company a “buy” rating in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft began coverage on Kymera Therapeutics in a research report on Thursday, July 30th. They issued a “hold” rating and a $120.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $137.92.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.